Ruiz 2003.

Methods	RETROGENE study N= 46 patients Randomized Open Fup: 48 weeks w/o d/o: reported
Participants	Eligibility:‐ 3 drug regimens* 6mo tmt failure * previous regimens VL>1,000 cop/ml, Baseline CD4 383 ( 84‐783) Baseline VL 4.3(3.2‐5.3) ART regimens: NRTI + NNRTI + PI duration: 5.73 years 77% MDR resistant STI: N=22 median age 32(25‐43) yrs, 76% males Controls: N= 24 age 35(23‐47) yrs, 73% males,
Interventions	12 weeks STI
Outcomes	CD4 cell count differences b/w STI and control gps: No difference between groups (p=0.734) VL <50 cop/ml at 48 weeks: STI gp 45% participants Control gp46% participants (no difference between gps, p=0.619) Viral Reversion: STI gp 35% participants
Notes	No immunological benefit of STI
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear